摘要
Tumor cells undergo rapid aerobic glycolysis to fuel growth and proliferation. A recent finding in Nature reveals that tumor-infiltrating myeloid cells demonstrate greater capacity for glucose uptake than tumor cells and consume significant amounts within the tumor milieu. Unexpectedly, tumor cells account for the highest glutamine utilization in the tumor microenvironment. Tumor cells undergo rapid aerobic glycolysis to fuel growth and proliferation. A recent finding in Nature reveals that tumor-infiltrating myeloid cells demonstrate greater capacity for glucose uptake than tumor cells and consume significant amounts within the tumor milieu. Unexpectedly, tumor cells account for the highest glutamine utilization in the tumor microenvironment. A fundamental notion of cancer biology may be flipped on its head. For decades, the field of cancer biology has understood that cancer cells undergo a metabolic phenomenon called the Warburg effect, in which cancer cells preferentially catabolize glucose through glycolysis even when abundant oxygen is present (Vander Heiden et al., 2009Vander Heiden M.G. Cantley L.C. Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation.Science. 2009; 324: 1029-1033Crossref PubMed Scopus (9348) Google Scholar). While inefficient in terms of net ATP output, aerobic glycolysis allows the tumor cells to quickly generate energy and intermediate metabolites, leading to rapid growth and proliferation (Vander Heiden et al., 2009Vander Heiden M.G. Cantley L.C. Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation.Science. 2009; 324: 1029-1033Crossref PubMed Scopus (9348) Google Scholar). With considerable attention focused on metabolism research and the understanding that cellular phenotypes and activity are intimately linked, one current trend in cancer research is to understand how manipulation of either tumor or immune cell metabolic programs can further improve the effectiveness and efficacy of cancer therapy. Moreover, cellular metabolism is further dependent on the availability of nutrients that fuel all of our internal metabolic processes. As such, in addition to overall metabolism, nutrient availability or partitioning within the tumor microenvironment could have a direct impact on whether our immune cells help or hinder an anti-tumor response. So what is happening to the nutrients in the tumor microenvironment? With the prevailing conception being that cancer cells devour glucose rapidly through Warburg glycolysis, it can seem counterintuitive that the nutrient most consumed within the tumor microenvironment is not glucose but rather the amino acid glutamine. And yet, that is just what Reinfeld et al. uncover in a new study published in Nature (Reinfeld et al., 2021Reinfeld B.I. Madden M.Z. Wolf M.M. Chytil A. Bader J.E. Patterson A.R. Sugiura A. Cohen A.S. Ali A. Do B.T. et al.Cell-programmed nutrient partitioning in the tumour microenvironment.Nature. 2021; 593: 282-288Crossref PubMed Scopus (116) Google Scholar). Using PET tracers, Reinfeld et al. measured glucose intake in both tumor cells and immune cells infiltrating in the tumor niche. This study reveals that tumor-infiltrating immune cells, in particular the myeloid cells which make up the innate immune system, are able to take up substantial amounts of glucose. In fact, the PET studies reveal that myeloid cells have a higher capacity for glucose uptake when compared to the cancer cells and account for a significant portion of the glucose consumption within the tumor microenvironment (∼30% of available glucose). This being said, tumor cells still consume the majority of the glucose (60%) within the tumor microenvironment due to the greater number of tumor cells compared to immune cells (Figure 1). Mechanistic target of rapamycin (mTOR) is a protein kinase that integrates nutrient availability and growth factor-and immune factor-initiated signaling (Liu and Sabatini, 2020Liu G.Y. Sabatini D.M. mTOR at the nexus of nutrition, growth, ageing and disease.Nat. Rev. Mol. Cell Biol. 2020; 21: 183-203Crossref PubMed Scopus (559) Google Scholar). Having observed that both myeloid and tumor cells take up the most glucose, Reinfeld et al. sought to determine whether this uptake was mediated by mTOR. Gene set enrichment analyses showed a significant enrichment of glucose-related pathways in both tumor and myeloid cells, and using Rapamycin to inhibit mTOR activity results in a significant loss of fluorodeoxyglucose (FDG) uptake, especially in myeloid cells. Interestingly, rapamycin does not affect the mitochondrial fitness nor the glycolysis of cancer cells but has large inhibitory effects on myeloid cells. Furthermore, the cancer cells are also found to enrich pathways associated with lipid metabolism and amino acid synthesis and have high expression of Mycn, a proto-oncogene that has been shown to drive glutaminolysis (Figure 1). Tumor-bearing mice were then treated with 18F-Gln, a fluorescently labeled glutamine. In contrast to glucose, they find that tumor cells have a significantly higher capacity for glutamine uptake, consuming ∼85% of the available glutamine within the tumor microenvironment (Figure 1). Interestingly, inhibition of glutamine uptake results in enhanced glucose consumption by cells within the tumor niche, suggesting that nutrient acquisition could be more so determined by cell-intrinsic properties rather than by what nutrients are available extrinsically. Taken together, these stunning revelations by Reinfeld et al. open the door for a number of intriguing questions regarding the future of nutrient partitioning studies within the tumor microenvironment. First, the role of myeloid cells within the tumor milieu has been of interest to tumor immunologists for some time. In particular, myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) have been the subject of much research due to their highly immunosuppressive properties and pro-tumoral effector function (Noy and Pollard, 2014Noy R. Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy.Immunity. 2014; 41: 49-61Abstract Full Text Full Text PDF PubMed Scopus (2128) Google Scholar; Veglia et al., 2021Veglia F. Sanseviero E. Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity.Nat. Rev. Immunol. 2021; https://doi.org/10.1038/s41577-020-00490-yCrossref PubMed Scopus (158) Google Scholar). And while MDSCs and TAMs are metabolically active cells, their role in nutrient sequestration has been critically overlooked—especially since glucose consumption is not often strongly associated with these particular cell types. Indeed, in terms of macrophage polarization, high glucose consumption is often attributed to pro-inflammatory (or M1) macrophages, which are often lowly presented within the tumor microenvironment (Noy and Pollard, 2014Noy R. Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy.Immunity. 2014; 41: 49-61Abstract Full Text Full Text PDF PubMed Scopus (2128) Google Scholar). However, anti-inflammatory (or M2) macrophages also require glucose. It has been reported that M2 macrophages increase glycolytic activity compared with naive macrophages, and this enhanced glucose utilization is necessary for M2 polarization (Huang et al., 2016Huang S.C.-C. Smith A.M. Everts B. Colonna M. Pearce E.L. Schilling J.D. Pearce E.J. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation.Immunity. 2016; 45: 817-830Abstract Full Text Full Text PDF PubMed Scopus (293) Google Scholar). Moreover, this utilization is mTORC2 dependent, with loss of mTORC2 in macrophages leading to enhanced anti-tumor immunity. This may suggest that treatments targeting glucose in the tumor microenvironment could work to inhibit immunosuppressive TAM differentiation. In addition to tumor-infiltrating myeloid cells, these findings call to question whether the oncogenic driver of a particular cancer instructs nutrient acquisition and whether the natural partitioning of the tissue environment itself could influence which nutrients are preferentially utilized. Previously, two excellent studies found that T cell dysfunction is driven in part by restricted glucose availability within the tumor microenvironment (Chang et al., 2015Chang C.-H. Qiu J. O’Sullivan D. Buck M.D. Noguchi T. Curtis J.D. Chen Q. Gindin M. Gubin M.M. van der Windt G.J.W. et al.Metabolic competition in the tumor microenvironment is a driver of cancer progression.Cell. 2015; 162: 1229-1241Abstract Full Text Full Text PDF PubMed Scopus (1421) Google Scholar; Ho et al., 2015Ho P.-C. Bihuniak J.D. Macintyre A.N. Staron M. Liu X. Amezquita R. Tsui Y.-C. Cui G. Micevic G. Perales J.C. et al.Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses.Cell. 2015; 162: 1217-1228Abstract Full Text Full Text PDF PubMed Scopus (731) Google Scholar). Interestingly, the tumor models used in these studies are driven by the oncogenes KRAS and BRAF, which are known to be associated with enhanced glycolytic metabolism (Nagarajan et al., 2016Nagarajan A. Malvi P. Wajapeyee N. Oncogene-directed alterations in cancer cell metabolism.Trends Cancer. 2016; 2: 365-377Abstract Full Text Full Text PDF PubMed Scopus (88) Google Scholar). This offers one potential avenue of study: do the oncogenes which drive tumorigenesis also contribute to nutrient partitioning? The fact that the Myc oncogene present in Reinfeld et al.’s tumor models is associated with glutaminolysis, and that glutamine was the highest nutrient consumed, it could stand to reason that the oncogenic driver of a tumor could potentially determine how nutrients are partitioned within the extracellular environment. Should this be the case, it could mean that metabolic therapies should be tailored for the primary metabolic pathways that are perturbed. Furthermore, nutrient availability and/or preferences differ based on the tissue niche. A comprehensive study by Jang et al. mapping metabolite production and consumption in mammals demonstrates surprising organ specificity (Jang et al., 2019Jang C. Hui S. Zeng X. Cowan A.J. Wang L. Chen L. Morscher R.J. Reyes J. Frezza C. Hwang H.Y. et al.Metabolite exchange between mammalian organs quantified in pigs.Cell Metab. 2019; 30: 594-606Abstract Full Text Full Text PDF PubMed Scopus (74) Google Scholar). It would, therefore, be interesting to see if the specific preference for certain nutrients is present in disparate tissue regions and results in different tumor metabolic rewiring. This work by Reinfeld et al. demonstrates that both tumors and immune cells take up nutrients within the tumor microenvironment, although at vastly different rates and amounts. This highlights the fact that different cellular subpopulations have different metabolic needs and thus acquire specific nutrients preferentially. Coupled with the vast heterogeneity of tumors and tissues, much consideration and further research will be needed to determine how these findings can be utilized to enhance cancer therapies. The authors declare no competing interests.